ISRCTN68222771 https://doi.org/10.1186/ISRCTN68222771

Efficacy of agomelatine given orally on the quality of remission in elderly depressed patients, after a 12-week treatment period. A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus SSRI drug. Twelve-week treatment plus optional continuation for 12 weeks.

Submission date 24/01/2006	<b>Recruitment status</b> No longer recruiting	Prospectively registered	
<b>Registration date</b> 31/03/2006	<b>Overall study status</b> Completed	Protocol     Statistical applysis also	
		<ul> <li>Statistical analysis plan</li> <li>[X] Results</li> </ul>	
	<b>Condition category</b> Mental and Behavioural Disorders	[ ] Individual participant data	
Last Edited 18/04/2018			

## Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

## **Contact information**

**Type(s)** Scientific

**Contact name** Dr Thierry Bougerol

**Contact details** CHU de Grenoble-Hopital Sud Psychiatrie de l'Adulte BP 185 Cedex 09 Grenoble France 38042

# Additional identifiers

**EudraCT/CTIS number** 2005-002388-95

**IRAS number** 

ClinicalTrials.gov number

Secondary identifying numbers CL3-20098-048

## Study information

### Scientific Title

Efficacy of agomelatine (25 to 50 mg/day) given orally on quality of remission in elderly depressed patients, after a 12-week treatment period.A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus paroxetine (20 to 30 mg/day).Twelve-week treatment plus optional continuation for 12 weeks.

#### **Study objectives**

To show the efficacy of agomelatine in improving the quality of remission in elderly depressed patients.

On 26/11/2012 the anticipated end date of this trial was updated from 30/10/2007 to 30/04 /2008.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

First approved by the Ethical Committee of Clinical Investigations, Clinical Hospital of San Carlos (Comite Etico de Investigacion Clinica, Hospital Clinico, San Carlos) on 05/08/2005 in Spain, reference number: 05/165-R

#### Study design

Randomised double-blind flexible-dose international multicentre study with parallel groups versus SSRI drug

**Primary study design** Interventional

**Secondary study design** Randomised controlled trial

**Study setting(s)** Not specified

**Study type(s)** Treatment

### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Major depressive disorder

### Interventions Agomelatine versus SSRI drug

Intervention Type Drug

**Phase** Not Applicable

### **Drug/device/biological/vaccine name(s)** Agomelatine

**Primary outcome measure** Quality of sleep

## Secondary outcome measures

- 1. Other sleep patterns
- 2. Quality of life
- 3. Daytime drowsiness
- 4. Residual symptoms of depression

## Overall study start date

07/10/2005

## Completion date

30/04/2008

# Eligibility

## Key inclusion criteria

Out-patients aged at least 60 years with recurrent major depressive episode according to diagnostic and statistical manual of mental disorders (DSM) IV

#### **Participant type(s)** Patient

**Age group** Adult

### **Sex** Both

## Target number of participants

400

### Key exclusion criteria

1. Patients treated with electroconvulsive therapy (ECT) within the last three months

2. Insight-oriented and structured psychotherapy started within the three months before inclusion

- 3. Light-therapy started within two weeks before inclusion
- 4. Current diagnosis of neurological disorders
- 5. Cognitive dysfunction
- 6. Severe or uncontrolled organic disease, likely to interfere with the conduct of the study

Date of first enrolment

07/10/2005

Date of final enrolment 30/04/2008

# Locations

## **Countries of recruitment**

Austria

Belgium

Denmark

France

Hungary

Italy

Norway

Poland

Portugal

Spain

**Study participating centre CHU de Grenoble-Hopital Sud** Grenoble France 38042

## Sponsor information

**Organisation** Institut de Recherches Internationales Servier (France)

## Sponsor details

50 rue Carnot Suresnes France 92284

**Sponsor type** Industry

Website http://www.servier.com/

ROR https://ror.org/034e7c066

# Funder(s)

Funder type Industry

**Funder Name** Institut de Recherches Internationales Servier (France)

# **Results and Publications**

## Publication and dissemination plan

Summary results are published in https://clinicaltrials.servier.com. For interventional Phase III studies ending after the 1st January 2014, the results are/will be published in scientific literature.

## Intention to publish date

## Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from https://clinicaltrials.servier.com if a Marketing Authorisation has been granted after 1st January 2014.

### IPD sharing plan summary

## Available on request

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Basic results				No	No
<u>Results article</u>	results	01/01/2013		Yes	No